Incretin strategy in the treatment of type 2 diabetes mellitus - DPPIV

Czech version

Authors: J. Perušičová
Authors‘ workplace: Diabetologické centrum Interní kliniky 2. lékařské fakulty UK a FN Motol, Praha, přednosta prof. MUDr., Milan Kvapil, CSc.
Published in: Vnitř Lék 2007; 53(9): 1005-1009
Category: Review

Overview

Administration of GLP-1 analogue resistant to DPPIV or therapeutic inhibition of the enzymes, allowing for an increase in the levels of GLP-1, are the very new approaches to the treatment of type 2 diabetes mellitus. Incretin therapy has an immense potential of improving unsatisfactory compensation in diabetic patients thus reducing the risk of manifestation of all arterial complications. Low fasting circulating levels of GLP-1 (and also GIP) grow rapidly after eating and are subsequently degraded to inactive forms by dipeptidyl peptidases IV (DPPIV). DPPIV are enzymes widely present in the body which proteolytically degrade GLP- 1 and GIP (as well as other active substances). The preventing of their inactivation effect by administering DPPIV inhibitors allows for increasing the GLP-1 levels, which are reduced in type 2 diabetic patients, and subsequently improves glucose homeostasis in such patients. DPPIV inhibitors represent the principal new class of PAD, and their metabolic profile offers a number of unique clinical advantages for the treatment of patients with type 2 diabetes mellitus.

Key words:
GLP-1 – DPPIV – type 2 diabetes mellitus

Sources

1. Ahrén B. What mediate the benefits associated with dipeptidyl peptidase-IV inhibition? Diabetologia 2005; 48: 605-607.

2. Ahrén B. Inhibition of dipeptidyl peptidase-IV reduces glycemia, sustains insulin levels and reduces glucagon levels in type 2 diabetes. J Clin Endocr Metab 2004; 89: 2078-2084.

3. Ahrén B. Gut peptides and type 2 diabetes mellitus treatment. Curr Diab Rep 2003; 3: 365-372.

4. Ahrén B Glucagon-like peptide 1 (GLP-1) - a gut hormone of potential interest in the treatment of diabetes. Bioesays 1998; 20: 642-651.

5. Bray GM. Exenatide. Am J Health Syst Pharm 2006; 63: 411-418.

6. Brunzell JD, Robertson RP, Lerner RL et al. Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests. J Clin Endocrinol Metab 1976; 42: 222-229.

7. Burcelin R, Dolci W, Thorens B. Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analog of glucagons-like peptide-1. Metabolism 1999; 48: 252-258.

8. Buse JB, Henry RR, Han J et al. for the Exenatide-113 Clinical Study Group: Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulphonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 2628-2635.

9. Creutzfeldt W, Ebert R: New developments in the incretin concept. Diabetologia 1985; 28: 565-573.

10. Drucker DJ. Minireview: the glucagon-like peptides. Endocrinology 2001; 142: 521-527.

11. Drucker DJ. Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes. Expert Opin Invest Drugs 2003; 12: 87-100.

12. Gautier JF, Fetita S, Sobngwi E et al. Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes. Diabetes Metab 2005; 31: 233-242.

13. Green BD, Irwin N, Flatt PR. Pituitary adenylate cyclase-activating peptide (PACAP): Assessment of dipeptidyl peptidase IV degradation, insulin-releasing activity and antidiabetic potential. Peptides 2006; 27: 1349-1358.

14. Holst JJ, Deacon FC. Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. Diabetologia 2005; 48: 612-615.

15. Hui H, Zhao X, Perfetti R. Structure and function studies of glucagon-like peptide 1 (GLP-1): the designing of a novel pharmacological agent for the treatment of diabetes. Diabetes Metab Res Rev 2005; 21: 313-331.

16. Hui H, Farila L, Merkel P et al. The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects. Eur J Endocrinol 2002; 146: 863-869.

17. Hu H, Norparvar A, Yhao X et al. Glucagon-like peptide-1 inhibits apoptosis of insulin secreting cells via a cyclic 5´adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway. Endocrinology 2003; 144: 1444-1455.

18. Hupe-Sodmann K, McGregor GP, Bridenbaugh R et al. Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for other glucagons-like peptides. Regul Pept 1995; 58: 149-156.

19. Gedulin BR, Nikoulina SE, Smith PA et al. Exenatide (exendin 4) improves insulin sensitivity and -cell mass in insulin resistant obese fa/fa Ucker rats independent of glycemia and body weight. Endocrinology 2005; 146: 2069-2076.

20. Iltz JL, Baker DE et al. Exenatide: An incretin mimetic for the treatment of type 2 diabetes mellitus. Clin Ther 2006; 28: 652-664.

21. Jeanfavre DD, Woska JR, Pargelis CA et al. Effect of deoxycoformycin and Val-boroPro on the associated catalytic activities of lymphocyte CD26 and ecto-adenosine deaminase. Biochem Pharmacol 1996; 52: 1757-1765.

22. Korom S, Meester I, Maas E et al. CD26 expression and enzymatic activity in recipients of kidney allografts. Transplant Proc 2002; 34: 1753-1754.

23. Kubota T, Flentke GR, Bachovchin WW et al. Involement of dipeptidyl peptidase IV in an in vivo immune response. Clin Exp Immunol 1992; 89: 192-197.

24. Lindsay JR, Duffyt NA, McKillop AM et al. Inhibition of dipeptidyl peptidase IV activity by oral metformin in type 2 diabetes. Diabet Med 2005; 22: 654-657.

25. Mannucci E, Pala L, Ciani S et al. Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus. Diabetologia 2005; 48: 1168-1172.

26. Mentlein R Dipetidyl-peptidase IV (CD26) - role in the inactivation of regulatory peptides. Regul Pept 1999; 85: 9-24.

27. Mest HJ, Mentlein R. Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes. Diabetologia 2005; 48: 616-620.

28. Moore B, Edie ES, Abram JH. On the treatment of diabetes mellitus by acid extract of duodenal mucous membrane. Biochem J 1906; 1: 28-38.

29. Nauck MA, El-Ouaghlidi A. The therapeutic actions of DPP-IV inhibition are not mediated by glucagons-like peptide-1. Diabetologia 2005; 48: 608-611.

30. O’Harte FP, Abdel-Wahab YH, Conlon JM et al. Glycation of glucagon-like peptide-1(7-36) amide: characterization and impaired action on rat insulin secreting cells. Diabetologia 1998; 41: 1187-1193.

31. Toft-Nielsen MB, Damholt MB, Madsbad S et al. Determinants of the impaired secretion of the glucagon-like peptide 1 in type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 3717-3723.

32. Tsu H, Chen X, Chen CT et al: 2-{3-{2-{(2S)-2-Cyano-1-pyrrolidinyl}-2-oxoethylamino}-3-methyl-1-oxobutyl}-1,2,3,4-tetrahydroisoquinoline: A potent, Sellective and Orally Bioavailable Dipeptide-Derived Inhibitor of Dipeptidyl Peptidase IV. J Med Chem 2006; 49: 373-380.

33. Unger RH, Eisentraut AM. Entero-insular axis. Arch Intern Med 1969; 124: 261-266.

34. Uwaifo GI, Ratner RE Novel pharmacologic agents for type 2 diabetes. Endocrinol Metab Clin N Am 2005; 34: 155-197.

35. Weber AE. Dipeptidyl Peptidase IV inhibitors for the treatment of diabetes. J Med Chem 2004; 47: 4135-4141.

36. Yamazaki K, Inoue T, Yasuda N et al. Comparison of efficacies of a dipeptidyl peptidase

IV inhibitor and alfa-glucosidase inhibitors in oral carbohydrate and meal tolerance tests and the effects of their combination in mice. J Pharmacol Sci 2007; 104: 29-38.

37. Yasuda N, Inoue T et al. Enhanced secretion of glucagon-like peptide 1 by biguanide compounds. Biochem Biophy Res Commun 2002; 298: 779-784.

38. Zander M, Taskiran M et al. Additive glucose-lowering effects of glucagon-like peptide-1 and metformin in type 2 diabetes. Diabetes Care 2001; 24: 720-725.

39. Zander M, Madsbad S, Deacon CF et al. The metabolite generated by dipeptidyl-peptidase 4 metabolism of glucagon-like peptide-1 has no influence on plasma glucose levels in patients with type 2 diabetes. Diabetologia 2005; 49: 369-374.